Eli Lilly's investigational sNSCLC drug meets Ph III endpoint

14 August 2013

US drug major Eli Lilly’s (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company said yesterday (August 13) that SQUIRE, a recently completed Phase III study, met its primary endpoint.

The study showed that patients with stage IV metastatic squamous non-small cell lung cancer (NSCLC) experienced increased overall survival (OS) when administered the firm’s necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as a first-line treatment, compared to chemotherapy alone.

Under a restructured deal with development partner Bristol-Myers Squibb (NYSE: BMY), the companies shared costs for developing necitumumab, and, if it is approved, B-MS would have receive 55 % of sales in the USA, Canada and Japan, while Lilly will retain all other revenue (The Pharma Letter January 29, 2010). However, along with its fourth-quarter 2012 financial results, B-MS said it has terminated its agreement for necitumumab with Lilly.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK